Home  About us  Contact
 

Optimizing Outcomes (optimizing + outcome)

Distribution by Scientific Domains
Medical Sciences100%

Selected Abstracts

Thursday, August 3 09:00,10:00 Optimizing Outcomes in BD

BIPOLAR DISORDERS, Issue 2006
Article first published online: 21 JUL 200
No abstract is available for this article. [source]

Optimizing outcomes for patients with severe haemophilia A

HAEMOPHILIA, Issue 2007
S. W. PIPE
First page of article [source]

Optimizing outcomes with incretin-based therapies: Practical information for nurse practitioners to share with patients

JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, Issue 2009
BC-ADM, C-RNP, CDE Nurse Practitioner, Evelyne Fleury-Milfort MSN, Instructor in Clinical Medicine
Abstract Purpose: To introduce the role of incretin therapies and suggest strategies for nurse practitioners to implement them in practice. Data sources: PubMed, Medline, summary of product characteristics/package inserts. Conclusions: Incretin-based therapies offer a new alternative to currently available agents. They provide adequate levels of glycemic control and are associated with low incidence of hypoglycemia and weight gain. Dipeptidyl peptidase-4 inhibitors, for example sitagliptin, have a modest effect on A1c levels (,0.7%) as monotherapy; however, they reduce A1c to a greater extent when combined with metformin (,2.0%). Typical starting dose of sitagliptin is 100 mg; dose adjustments are required in subjects with renal complications. Glucagon-like peptide-1 receptor agonists, exenatide and liraglutide, reduce A1c levels (often in excess of 1.5%) and body weight. Exenatide has a starting dose of 5 ,g and is not recommended for patients with hepatic impairment or severe/end-stage renal disease. Liraglutide has been found to benefit from a stepwise dose escalation (i.e., 0.6 mg weekly increments) until a 1.8-mg dose is reached. Unlike exenatide, dose adjustments in patients with renal and hepatic complications are not required. Implications for practice: Incretin-based therapies may help to overcome some of the drawbacks of current therapies used to treat type 2 diabetes. [source]

Optimizing outcomes in patients with serious Gram-positive infections

CLINICAL MICROBIOLOGY AND INFECTION, Issue 2009
J. M. Miró
No abstract is available for this article. [source]

Surge Capacity for Healthcare Systems: A Conceptual Framework

ACADEMIC EMERGENCY MEDICINE, Issue 11 2006
Amy Kaji MD
This report reflects the proceedings of a breakout session, "Surge Capacity: Defining Concepts," at the 2006 Academic Emergency Medicine Consensus Conference, "Science of Surge Capacity." Although there are several general descriptions of surge capacity in the literature, there is no universally accepted standard definition specifying the various components. Thus, the objectives of this breakout session were to better delineate the components of surge capacity and to outline the key considerations when planning for surge capacity. Participants were from diverse backgrounds and included academic and community emergency physicians, economists, hospital administrators, and experts in mathematical modeling. Three essential components of surge capacity were identified: staff, stuff, and structure. The focus on enhancing surge capacity during a catastrophic event will be to increase patient-care capacity, rather than on increasing things, such as beds and medical supplies. Although there are similarities between daily surge and disaster surge, during a disaster, the goal shifts from the day-to-day operational focus on optimizing outcomes for the individual patient to optimizing those for a population. Other key considerations in defining surge capacity include psychosocial behavioral issues, convergent volunteerism, the need for special expertise and supplies, development of a standard of care appropriate for a specific situation, and standardization of a universal metric for surge capacity. [source]